GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Scaled Net Operating Assets

GlaxoSmithKline Pakistan (KAR:GLAXO) Scaled Net Operating Assets : 0.43 (As of Sep. 2024)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

GlaxoSmithKline Pakistan's operating assets for the quarter that ended in Sep. 2024 was ₨40,564 Mil. GlaxoSmithKline Pakistan's operating liabilities for the quarter that ended in Sep. 2024 was ₨21,832 Mil. GlaxoSmithKline Pakistan's Total Assets for the quarter that ended in Jun. 2024 was ₨43,349 Mil. Therefore, GlaxoSmithKline Pakistan's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.43.


GlaxoSmithKline Pakistan Scaled Net Operating Assets Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Scaled Net Operating Assets Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.49 0.47 0.54 0.51

GlaxoSmithKline Pakistan Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.47 0.51 0.47 0.43

Competitive Comparison of GlaxoSmithKline Pakistan's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Scaled Net Operating Assets falls into.



GlaxoSmithKline Pakistan Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

GlaxoSmithKline Pakistan's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(34520.142-16303.088)/35541.907
=0.51

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=38130.899 - 3610.757
=34520.142

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=16455.058 - 116.035 - 35.935
=16303.088

GlaxoSmithKline Pakistan's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(40563.892-21831.791)/43348.799
=0.43

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=47256.928 - 6693.036
=40563.892

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=21999.803 - 144.091 - 23.921
=21831.791

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pakistan Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in research, development, and manufacturing pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines